A new pre-clinical study on Glucevia shows a preventive effect on hepatic steatosis and suggests a mechanism of action through liver metabolism.
 
Eighty percent of adults are willing to use supplements to prevent high blood sugar levels according to the 2012 Gallup study of nutrient knowledge and consumption— a health factor that can lead to type 2 diabetes. The market potential is huge and opens up possibilities for new ingredients. Glucevia is an extract of Fraxinus (ash) derived from its seeds/fruits that helps to regulate glycemia naturally. The efficacy and safety of this unique extract on blood sugar control has been demonstrated via 7 scientific studies, including 3 clinical trials, according to the company.
 
The latest pre-clinical study published in the Journal of Diabetes and Metabolism found that Glucevia decreases insulin resistance while reducing fatty liver in diabetic mice after seven months of administration. The liver of supplemented mice presented 54% less fat droplets than the control group. This demonstrates that non-alcoholic steatosis in the liver was markedly reduced in treated mice thanks to Glucevia.
 
A previous clinical study demonstrated that daily consumption of 1,000 mg of Glucevia for three weeks reduces the incremental glucose area under the curve (AUC) by 28.2% vs. baseline. “Studies on Glucevia have shown an improved glucose tolerance in humans and the reduction of long term insulin resistance in mice. These results support the potential of this unique ingredient for use in blood sugar management,” said Dr. Antoine Bily, R&D director at Naturex.
 
“We will continue investigating Glucevia’s hepatoprotective function because non-alcoholic fatty liver disease is the main manifestation of insulin resistance and is linked to metabolic syndrome,” he continued. “Currently, only a few preventive supplements exist and there is no evidence-based approved therapy to manage this common chronic disease in Western countries.” 
 
For more information: www.naturex.com